

**Supplementary table 1.** Analysis of the literature data.

First author	Study design	All adverse reactions, n (%)		Severe adverse reactions, n (%)		CP infusion-related adverse reactions, n (%)		Thromboembolic adverse reactions, n (%)	
		CP group	ST group	CP group	ST group	All	Severe	CP group	ST group
Abolghashemi <sup>1</sup>	NRCT	NA	NA	NA	NA	1/115 (0.9)	0/115	NA	NA
Ah Yoon <sup>2</sup>	NRCT	NA	NA	NA	NA	0/73	0/73	NA	NA
AlQahtani <sup>3</sup>	RCT	3/20 (15.0)	0/20	0/20	0/20	0/20	0/20	0/20	0/20
Alsharidah <sup>4</sup>	NRCT	NA	NA	NA	NA	3/135 (2.2)	0/135	NA	NA
AlShehri <sup>5</sup>	NRCT	NA	NA	NA	NA	0/40	0/40	NA	NA
Bajpai <sup>6*</sup>	RCT	1/14 (7.1)	1/15 (6.7)	0/14	0/15	1/14 (7.1)	0/14	NA	NA
Balcells <sup>7**</sup>	RCT	4/41 (9.8)	-	3/41 (7.3)	-	2/41 (4.9)	1/41 (2.4)	0/41	-
Budhiraja <sup>8</sup>	NRCT	NA	NA	NA	NA	2/333 (0.6)	0/333	NA	NA
ConCOVID Trial <sup>9</sup>	RCT	NA	NA	NA	NA	0/43	0/43	NA	NA
ConPlas-19 Study <sup>10</sup>	RCT	NA	NA	6/38 (15.8)	7/43 (16.3)	2/38 (5.3)	2/38 (5.3)	1/38 (2.6)	2/43 (4.6)
Donato <sup>11</sup>	NRCT	NA	NA	NA	NA	1/51 (2.0)	0/51	NA	NA
Duan <sup>12</sup>	NRCT	NA	NA	NA	NA	1/10 (10.0)	0/10	0/10	NA
Hamdy Salman <sup>13</sup>	RCT	NA	NA	NA	NA	0/15	0/15	NA	NA
Hatzl <sup>14</sup>	NRCT	NA	NA	NA	NA	0/48	0/48	NA	NA
Klapholz <sup>15</sup>	NRCT	NA	NA	NA	NA	0/47	0/47	NA	NA

Li <sup>16</sup>	RCT	2/52 (3.8)	0/51	1/52 (1.9)	0/52	2/52 (3.8)	1/52 (1.9)	0/52	0/51
Libster <sup>17</sup>	RCT	0/79	1/80 (1.2)	0/79	0/80	0/80	0/80	0/79	1/80 (1.2)
Liu <sup>18</sup>	NRCT	NA	NA	NA	NA	0/39	0/39	NA	NA
Moniuszko-Malinowska <sup>19</sup>	NRCT	NA	NA	NA	NA	0/78	0/78	NA	NA
O'Donnell <sup>20*</sup>	RCT	96/147 (65.3)	40/72 (55.6)	39/147 (26.5)	26/72 (36.1)	4/147 (2.7)	2/147 (1.4)	6/147 (4.1)	3/72 (4.2)
Pappa <sup>21</sup>	NRCT	4/59 (6.8)	NA	1/59 (1.7)	NA	1/59 (1.7)	1/59 (1.7)	NA	NA
PLACID Trial <sup>22</sup>	RCT	NA	NA	3/235 (1.3)	0/229	3/235 (1.3)	3/235 (1.3)	NA	NA
PlasmAr Study <sup>23</sup>	RCT	153/228 (67.1)	66/105 (62.9)	54/228 (23.7)	19/105 (18.1)	13/228 (5.7)	NA	4/228 (1.7)	0/105
Rasheed <sup>24</sup>	RCT	NA	NA	NA	NA	1/21 (4.8)	0/21	NA	NA
Ray <sup>25</sup>	RCT	NA	NA	NA	NA	0/40	0/40	NA	NA
Rogers <sup>26</sup>	NRCT	NA	NA	NA	NA	3/64 (4.7)	3/64 (4.7)	Na	NA
Salazar <sup>27</sup>	NRCT	NA	NA	NA	NA	7/351 (2.9)	2/351 (0.6)	NA	NA
Recovery Trial <sup>28</sup>	RCT	1433/5267 (27.2)	1427/5128 (27.8)	NA	NA	13/5795 (0.2)	13/5795 (0.2)	73/5267 (1.4)	87/5128 (1.7)
Xia <sup>29</sup>	NRCT	NA	NA	NA	NA	3/138 (2.2)	0/138	NA	NA
Zeng <sup>30</sup>	NRCT	NA	NA	NA	NA	0/6	0/6	NA	NA

Legend: RCT, randomized controlled trial; NRCT, non-randomized controlled trial; CP, convalescent plasma; ST, standard treatment; NA, not available.

\*Control group received non-hyperimmune normal plasma.

\*\*Early versus deferred convalescent plasma.

## References

1. Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. *Transfus Apher Sci.* 2020;59:102875.
2. Yoon HA, Bartash R, Gendlina I, et al. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC. *JCI Insight.* 2021;6(4):e142270.
3. AlQahtani M, Abdulkarim A, Almadani A, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. *medRxiv.* 2020; Available at: <https://www.medrxiv.org/content/10.1101/2020.11.02.20224303v1.full>.
4. Alsharidah S, Ayed M, Ameen RM, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. *Int J Infect Dis.* 2021;103:439-446.
5. AlShehry N, Zaidi SZA, AlAskar A, et al.; KSA COVID-19 Convalescent Plasma Study Group. Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia. *Saudi J Med Med Sci.* 2021;9(1):16-23.
6. Bajpai M, Kumar S, Maheshwari A, et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. *medRxiv.* 2020;Preprint. doi: 10.1101/2020.10.25.20219337
7. Balcells ME, Rojas L, Le Corre N, et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized Phase II clinical trial. *PLoS Med.* 2021;18(3):e1003415.
8. Budhiraja S, Dewan A, Aggarwal R, et al. Effectiveness of convalescent plasma in Indian patients with COVID-19. *Blood Cells Mol Dis.* 2021;88:102548.

9. Gharbharan A, Jordans CCE, Geurtsvankessel C, et al. Convalescent plasma for COVID-19: a randomized clinical trial. *medRxiv*. 2020;Preprint. Available at: <https://www.medrxiv.org/content/10.1101/2020.07.01.20139857v1>.
10. Avendano-Sola C, Ramos-Martinez A, Muñoz-Rubio E, et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. *medRxiv*. 2020;Preprint. Available at: <https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v3.full.pdf>.
11. Donato ML, Park S, Baker M, et al. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. *JCI Insight*. 2021;6(6):e143196.
12. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;117:9490–9496.
13. Hamdy Salman O, Ail Mohamed HS. Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. a double-blinded controlled preliminary study. *Egyptian J Anaesth*. 2020;36(1):264-272.
14. Hatzl S, Posch F, Sareban N, et al. Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. *Ann Intensive Care*. 2021;11(1):73.
15. Klapholz M, Pentakota SR, Zertuche JP, McKenna M, Roque W, Forsberg M, Packer J, Lal DS, Dever L. Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients. *Open Forum Infect Dis*. 2021;8(2):ofab001.
16. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA*. 2020;324(5):460-470.

17. Libster R, Pérez Marc G, Wappner D, et al; Fundación INFANT–COVID-19 Group. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med.* 2021;384(7):610-618.
18. Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. *Nat Med.* 2020;26(11):1708-1713.
19. Moniuszko-Malinowska A, Czupryna P, Zarębska-Michaluk D, et al. Convalescent Plasma Transfusion for the Treatment of COVID-19-Experience from Poland: A Multicenter Study. *J Clin Med.* 2020;10(1):28.
20. O'Donnell MR, Grinsztejn B, Cummings MJ, et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. *medRxiv.* 2021;Preprint. Available at: <https://www.medrxiv.org/content/10.1101/2021.03.12.21253373v1?%25253fcollection=>.
21. Pappa V, Bouchla A, Terpos E, et al. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. *Microorganisms.* 2021;9(4):806.
22. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P; PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ.* 2020;371:m3939.
23. Simonovich VA, Burgos Prats LD, Scibona P, et al; PlasmAr Study Group. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N Engl J Med.* 2021;384(7):619-629.
24. Rasheed AM, Fatak DF, Hashim HA, et al The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. *Infez Med.* 2020;28(3):357-366.

25. Ray Y, Paul SR, Bandopadhyay P, et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. *medRxiv*. 2020; Preprint. Available at: <https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1>.
26. Rogers R, Shehadeh F, Mylona EK, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. *Clin Infect Dis*. 2020 Oct 10:ciaa1548.
27. Salazar E, Christensen PA, Graviss EA, et al. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. *Am J Pathol*. 2021;191(1):90-107.
28. The RECOVERY Collaborative Group, Horby PW, Estcourt L, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *medRxiv*. 2021; Preprint. Available at: <https://www.medrxiv.org/content/10.1101/2021.03.09.21252736v1>.
29. Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. *Blood*. 2020;136:755–9.
30. Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. *J Infect Dis*. 2020;222:38–43.